The new 候选药物 RCI001 currently under development delivers 抗炎 effects through the selective modulation of multifunctional signaling molecules.
Moreover, it has shown improvement in 泪液分泎 function, and is currently being developed as an 滴眼液 with the goal of entering 临床试验 domestically and internationally next year. RCI001 played a key role in being selected for the '研发 Rediscovery Project' and other programs.